To the Editor.
—We read with interest the article by Fett et al1 regarding the injection of moxalactam into rabbit vitreous. Their findings that doses of 1.25 mg injected into the vitreous produced no toxic damage to the retina are similar to our data in which we demonstrated that doses of 2 mg or less were not associated with any demonstrable retinal toxicity. Our article,2 which was published in 1982, is the only other study to date which has examined the use of moxalactam in the eye. In addition to the toxicity studies, we examined the in vivo effectiveness of moxalactam in experimental staphylococcal endophthalmitis. Nine of nine eyes inoculated with Staphylococcus aureus and injected with 2 mg of moxalactam were sterile at the end of the treatment period. Focal retinal irregularities were observed in three eyes. These irregularities were presumably related to the injection technique. We also
Leeds NH, Peyman GA. Intravitreal Moxalactam. Arch Ophthalmol. 1984;102(9):1267–1268. doi:10.1001/archopht.1984.01040031027009
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.